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Neuroleptic malignant syndrome (NMS) is an emergent, often 
fatal, medical condition associated with the use of dopamine 
receptor antagonist medications.1,5 Hyperthermia, muscle 
rigidity, autonomic instability, evidence of muscle injury, and 
altered mental status are known to be the hallmarks of the 
disease2. In contrast with the typical presentation, atypical 
NMS presents with a different set of symptoms, making 
diagnosis difficult.2 It is important to use clinical acumen to 
make a timely and efficient diagnosis of NMS. We present a 
case of Atypical NMS in a 21 year old male. 
Discussion
A 21-year-old African American male with previous psychiatric 
history of “schizophrenia, bipolar disorder, acute dystonia, and 
tardive dyskinesia” was transferred to the emergency 
department from county jail, where he was being held for 
disturbing the peace, and assault. He was brought to the ED 
with a history of 2 to 3 days of  decreased activity, not eating,  
drooling, “howling”, and altered mental status. During this time 
patient was in isolation for previously erratic behavior.  
Conversations with staff at jail state that he was tachycardic 
and hypertensive at times during this episode yet when asked 
for full records they declined and explained they “don’t keep” 
charts or records. Jail nurses were able to tell us his 
medications include haloperidole decanoate, oral haloperidole 
and trihexylphenidyl yet he had been refusing medications in 
recent days to weeks. They were unable to provide 
information regarding PRN medications given during this 
period of time. On admission vital signs were as follows:  BP 
128/80, HR 113, Temp. 97.6, RR 20, O2 Sat. 99%. He 
expressed much pain and immobility. He was able to 
communicate with small head movements, grunts, and finger 
movements. Exam showed posturing, bradykinesia, trismus, 
sialorrhea, diaphoresis, and urinary incontinence. Lab findings 
indicated elevated creatinine kinase of 18,963 IU/L, WBC of 
14.2 x10^9/L, AST 330 IU/L, and ALT 98 IU/L. Iron studies 
showed the following: iron 42 mcg/dL, ferritin 293 ng/mL, iron 
sat 20%, transferrin 168 mg/dL, TIBC 213 mcg/dL. CT of head 
was unremarkable. Throughout the hospitalization he 
displayed no cogwheeling, no muscle rigidity, no 
hyperthermia, and no obvious cognitive dulling. He did not 
respond to 2mg lorazepam IV nor 10mg diazepam q8hrs IV for 
1 ½ days. Due to components of the history and physical 
exam, laboratory and imaging studies, it was determined that 
this patient was presenting with atypical NMS and 
bromocriptine therapy was initiated. The patient steadily 
improved back to baseline over a 22 day admission. 
It is essential to recognize NMS to prevent associated 
mortality. Mortality rates of unrecognized NMS are estimated 
to be 10%-20%.3 The presentation of NMS may vary 
significantly, making the diagnosis difficult to ascertain; 
however, key lab values are of diagnostic value. Initially, the 
differential included NMS, catatonia, and anticholinergic 
delirium. Catatonia was a less likely diagnosis as lorazepam 
2mg IV push demonstrated no improvement of symptoms. 
Anticholinergic delirium usually presents with altered mental 
status rather than movement disorder. CK and AST were 
elevated due to sustained muscle rigidity and 
rhabdomyolysis, this supports the diagnosis of NMS.7 Serum 
iron levels below 55.8 mcg/dL is also associated with NMS. 4 
Low serum iron concentration is an acute phase reactant in 
NMS and acts as a helpful adjunctive biochemical marker.4 
The presentation of NMS may be insidious over days. Most 
cases present within 3 days, though some may be up to 30 
days. The patient was treated with bromocriptine and there 
was significant improvement. Once diagnosis is made, 
antipsychotic medications should be held and re-challenging 
the patient with an antipsychotic can occur after a 5-14 day 
washout period from symptoms. Our patient was started on 
aripiprazole and titrated up to 15mg TID. 
In conclusion, NMS can present with a variety of 
symptoms. Recognizing atypical presentations of NMS is very 
important. Several sources propose various characteristic 
symptoms of atypical NMS including tremor, sialorrhea, 
akinesia, dystonia, trismus, myoclonus, dysarthria, dysphagia, 
diaphoresis, urinary incontinence, pallor, elevated CPK, 
leukocytosis, low serum iron, and elevated liver enzymes, 
often but not always associated with the classic features.1-4  
Our patient exhibited many of the proposed characteristics of 
NMS (posturing, bradykinesia, trismus, sialorrhea, 
diaphoresis, and urinary incontinence) yet he did not present 
with any of the “hallmark” features. The elevated creatine 
kinase, leukocytosis, transaminitis, and iron studies were 
helpful in making the diagnosis. 
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